Jia Shuqin, Cai Jun
Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff, U.K. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Molecular Oncology, Peking University Cancer Hospital and Institute, Beijing, P.R. China.
Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff, U.K.
Anticancer Res. 2016 Mar;36(3):1111-8.
The treatment of advanced gastric cancer remains challenging as the outcomes achieved with surgery alone or adjuvant or neoadjuvant chemotherapy and radiotherapy are poor. New treatment strategies are emerging and being tested in advanced gastric cancer. Vascular endothelial growth factor (VEGF) inhibitors have been confirmed as important therapeutic agents in randomised clinical trials in multiple solid tumour settings. Until now, results of phase II and phase III clinical trials of anti-angiogenic agents on gastric cancer have been relatively modest, with moderate improvement in overall survival. The effects of these drugs are limited due to development of resistance to them and the increased risk of tumour invasion and metastasis. If we are to optimise or develop combination regimens for advanced gastric cancer with VEGF inhibitors that build on their efficacy, it is critical to identify and validate biomarkers in order to enable selection of those patients who are prone to benefit and monitor their response to the drugs. Validated biomarkers can help to further personalise VEGF inhibitors and dosage determination for advanced or metastatic gastric cancer, particularly as these drugs can be toxic and expensive. Although no biomarker is validated for routine use for this purpose, several candidates are currently under investigation. In this review, we aim to give an overview of the recent developments in biomarkers for anti-angiogenic therapy in gastric cancer tumour angiogenesis.
晚期胃癌的治疗仍然具有挑战性，因为单独手术或辅助或新辅助化疗及放疗所取得的治疗效果较差。新的治疗策略不断涌现，并正在晚期胃癌中进行试验。血管内皮生长因子（VEGF）抑制剂已在多种实体瘤的随机临床试验中被确认为重要的治疗药物。到目前为止，抗血管生成药物在胃癌的II期和III期临床试验结果相对一般，总体生存率仅适度提高。由于对这些药物产生耐药性以及肿瘤侵袭和转移风险增加，这些药物的疗效有限。如果我们要优化或开发基于VEGF抑制剂疗效的晚期胃癌联合治疗方案，识别和验证生物标志物以选择可能受益的患者并监测他们对药物的反应至关重要。经过验证的生物标志物有助于进一步实现晚期或转移性胃癌VEGF抑制剂的个体化治疗及剂量确定，特别是因为这些药物可能有毒且昂贵。虽然目前尚无用于此目的的常规验证生物标志物，但目前有几种候选物正在研究中。在本综述中，我们旨在概述胃癌肿瘤血管生成中抗血管生成治疗生物标志物的最新进展。
